文献リスト

1) Kalk H. Fatty liver. Munch Med Wochenschr. 1965; 107: 1141-7

2) Robbers H, Strohfeldt P, Kruger C. Differential diagnosis of diabetic and alcoholic fatty liver. Studies on 171 diabetics and 100 patients with alcohol abuse. Dtsch Med Wochenschr. 1968; 93: 112-3

3) Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434-8

4) Neuschwander-Teri BA, Caldwell SH. Non-alcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37: 1202-19

5) Sasaki A, Horiuchi N, Hasegawa K, et al. Mortality and causes of death in type 2 diabetic patients. A long-term follow-up study in Osaka Distrinct, Japan. Diabetes Res Clin Pract. 1989; 7: 33-40

6) 谷川久一. 肝を中心とする代謝調節異常. 医学のあゆみ別冊. NAFLDのすべて. 2006; 4-9

7) Kohjima M, Higuchi N, Kato M, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med. 2008; 21: 507-11

8) Schultz JR, Tu H, Luk A. Role of LXRs in control of lipogenesis. Genes Dev. 2000; 14: 2831-8

9) Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem. 2007; 282: 743-51

10) Day CP, James OF. Steatohepatitis: a tale of two “hits"？ Gastroenterology. 1998; 114: 842-5

11) Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 21: 27-41

12) Merriman RB, Aouizerat BE, Bass NM. Genetic influences in nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006; 40 Suppl 1: S30-3

13) Namikawa C, Shu-Ping Z, Vyselaar JR. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol. 2004; 40: 781-6

14) Nozaki Y, Saibara T, Nemoto Y, et al. Polymorphisms of interleukin-1 beta and beta 3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis. Alcohol Clin Exp Res. 2004; 28(8 Suppl Proceedings): 106S-110S

15) Musso G, Gambino R, De Michieli F, et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology. 2008; 47: 1167-77

16) Yoneda M, Hotta K, Nozaki Y, et al. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2008; 8: 27

17) Merriman R, Aouizerat B, Molloy M, et al. A genetic mutation in the peroxisome proliferator-activated receptor alpha gene in patients with non-alcohoic steatohepatitis. Hepatology. 2001; 34: 441A

18) Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymor-phisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002; 122: 274-80

19) Song J, da Costa KA, Fischer LM, et al. Polymorphism of the PEMT gene and sus-ceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 2005; 19: 1266-71

20) Dong H, Wang J, Li C, et al. The phosphat-idylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese popula-tion. J Hepatol. 2007; 46: 915-20

21) Miele L, Beale G, Patman G, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology. 2008; 135: 282-91

22) Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004; 99: 1708-17

23) Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001; 34: 1158-63

24) Fromenty B, Robin MA, Igoudjil A, et al. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004; 30: 121-38

25) Sreekumar R, Rosado B, Rasmussen D, et al. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003; 38: 244-51

26) Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005; 25: 760-71

27) Yoneda M, Endo H, Mawatari H, et al. Gene expression profiling of non-alcoholic steato-hepatitis using gene set enrichment analysis. Hepatol Res. In press

28) Neuschwander-Tetri BA. Nonalcoholic steato-hepatitis: an evolving diagnosis. Can J Gastroenterol. 2000; 14: 321-6

29) Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123: 745-50

30) Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary？ Eur J Gastroenterol Hepatol. 2003; 15: 539-43

31) Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43 2 Suppl 1: S99-112

32) Cadranel JF. Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future. Gastroenterol Clin Biol. 2002; 26: 823-4

33) Iijima H, Moriyasu F, Tsuchiya K, et al. Decrease in accumulation of ultrasound contrast micro-bubbles in non-alcoholic steatohepatitis. Hepatol Res. 2007; 37: 722-30

34) Yoneda M, Yoneda M, Fujita K, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007; 56: 1330-1

35) Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008; 40: 371-8

36) Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007; 5: 1207-13

37) Uygun A, Kadayifci A, Yesilova Z, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2000; 95: 3584-9

38) Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity？ Hepatology. 2002; 36: 403-9

39) Nakao K, Nakata K, Ohtsubo N, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol. 2002; 97: 1796-801

40) Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin？ Hepatology. 2004; 40: 46-54

41) Musso G, Gambino R, Biroli G, et al. Hypo-adiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2005; 100: 2438-46

42) Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005; 90: 3498-504

43) Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005; 54: 117-21

44) Yoneda M, Iwasaki T, Fujita K, et al. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue. Alcohol Clin Exp Res. 2007; 31(1 Suppl): S15-21

45) Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107: 391-7

46) Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805-12

47) Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003; 107: 671-4

48) Hui JM, Farrell GC, Kench JG, et al. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology. 2004; 39: 1458-9

49) Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007; 42: 573-82

50) Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol. 2006; 45: 879-81

51) Iwasaki T, Nakajima A, Yoneda M, et al. Relationship between the serum concentrations of C-reactive protein and parameters of adiposity and insulin resistance in patients with type 2 diabetes mellitus. Endocr J. 2006; 53: 345-56

52) Capristo E, Miele L, Forgione A, et al. Nutritional aspects in patients with non-alcoholic steato-hepatitis (NASH). Eur Rev Med Pharmacol Sci. 2005; 9: 265-8

53) Sato F, Tamura Y, Watada H, et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab. 2007; 92: 3326-9

54) Marubbio AT Jr, Buchwald H, Schwartz MZ, et al. Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass. Am J Clin Pathol. 1976; 66: 684-91

55) Campbell JM, Hunt TK, Karam JH, et al. Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med. 1977; 137: 602-10

56) Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg. 2006; 16: 1278-86

57) Barker KB, Palekar NA, Bowers SP, et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol. 2006; 101: 368-73

58) Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005; 242: 610-20

59) Lutchman G, Promrat K, Kleiner DE, et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol. 2006; 4: 1048-52

60) Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007; 46: 424-9

61) Murphy CE, Rodgers PT. Effects of thiazoli-dinediones on bone loss and fracture. Ann Pharmacother. 2007; 41: 2014-8

62) Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100: 1082-90

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp